Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Blood (2025) 146 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2025-3730

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Blood (2025) 146 (Supplement 1): 3671.

https://doi.org/10.1182/blood-2025-3671

Published: 2025

Journal Articles

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Yun Kyoung Tiger, Roshan Asrani, Graham Wehmeyer, Robert Ryan, Ajay Major, Natalie Grover, Kelsey Baron, Talal Hilal, Adrienne Nedved, Taylor Brooks, Arjun Ravishankar, Tarsheen Sethi, Brian Hill, Yucai Wang, Allison Bock, Adam Kittai, Matthew Matasar, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2025-1956

Published: 2025

Journal Articles

Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study

Jean-Marie Michot, Munci Yagci, Katherine Kargus, Hesham Mohamed, Jingxiao Chen, Jurriaan Brouwer-Visser, Aafia Chaudhry, Nazia Iqbal, Matthew Matasar

Blood (2025) 146 (Supplement 1): 65.

https://doi.org/10.1182/blood-2025-65

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial

Adam Olszewski, Matthew Matasar, Scott Huntington, Dennis Bonal, Thomas Ollila, Ari Pelcovits, Yun Kyoung Tiger, John Reagan, Anna Chorzalska, John Morgan, Makayla Pardo, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Charles Milrod, Patrycja Dubielecka

Blood (2025) 146 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2025-1003

Published: 2025

Journal Articles

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Peng Liu, Koji Kato, Sai Li, Lara Chayab, Adriano Sa, Connie Lee Batlevi, Matthew Matasar

Blood (2025) 146 (Supplement 1): 8082.

https://doi.org/10.1182/blood-2025-8082

Published: 2025

Journal Articles

Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton's tyrosine kinase inhibitors

Tisheeka Graham, Tariqa Ackbarali, Katie Kowalski, Anita Kumar, Matthew Matasar, Caron Jacobson, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8106.

https://doi.org/10.1182/blood-2025-8106

Published: 2025

Journal Articles

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2025-1850

Published: 2025

Journal Articles

Time-stratified risk of second primary solid malignancies among follicular lymphoma survivors in the United States

Merry Zhai, Matthew Matasar, Anand Shah, Benjamin Bates

Blood (2025) 146 (Supplement 1): 5371.

https://doi.org/10.1182/blood-2025-5371

Published: 2025

Journal Articles

Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States

Matthew Matasar, Anthony Masaquel, Carolina Reyes, Farah Hossain, Eric Zuk, Rebecca Straubing, Matthew Davis, Scott Huntington

Blood (2025) 146 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2025-4486

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy

Ari Pelcovits, Makayla Pardo, Diana Treaba, Anna Chorzalska, Patrycja Dubielecka, Thomas Ollila, John Reagan, Matthew Matasar, Scott Huntington, Petra den Hollander, Sendurai Mani, Adam Olszewski

Blood (2025) 146 (Supplement 1): 5327.

https://doi.org/10.1182/blood-2025-5327

Published: 2025

Journal Articles

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Max S. Topp, Matthew Matasar, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O’Brien, Uri Abadi, Irit Avivi, Yuan Cheng, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2025) 145 (14): 1498–1509.

https://doi.org/10.1182/blood.2024027044

Published: 2025

Includes: Supplemental data

Journal Articles

Practice Patterns Inform Patient-Centered Approaches for the Integration of BTK Inhibitors in Frontline Mantle Cell Lymphoma

Tisheeka Graham, Tariqa Ackbarali, Anita Kumar, Matthew Matasar

Blood (2024) 144 (Supplement 1): 7785.

https://doi.org/10.1182/blood-2024-208930

Published: 2024

Journal Articles

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Adam J. Olszewski, Matthew Matasar, Scott F Huntington, Thomas Ollila, Ari Pelcovits, Yun Kyoung Tiger, John L. Reagan, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Charles Milrod, Patrycja M. Dubielecka

Blood (2024) 144 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2024-193022

Published: 2024

Journal Articles

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Blood (2024) 144 (Supplement 1): 3132.1.

https://doi.org/10.1182/blood-2024-194909

Published: 2024

Journal Articles

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Matthew Matasar, Katherine L Rosettie, Almut Mecke, Danilo Di Maio, Shih-Wen Lin, Mei Wu, Esprit Ma

Blood (2024) 144 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2024-198657

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review

Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton's tyrosine kinase inhibitors

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Time-stratified risk of second primary solid malignancies among follicular lymphoma survivors in the United States

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Practice Patterns Inform Patient-Centered Approaches for the Integration of BTK Inhibitors in Frontline Mantle Cell Lymphoma

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only